EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Discordant Primary Tumor and Nodal Response After Neoadjuvant Chemoimmunotherapy Identifies an Adverse Postoperative Subgroup in Esophageal Squamous Cell Carcinoma

Yuxian Qian, Yuting Ren, Zhiyun Xu iD, Rutao Li, Yipeng Feng, Hanlin Ding, Yijian Zhang, Wenjie Xia, Lin Xu, Gaochao Dong iD, Feng Jiang iD

Cancer Medicine · 2026-11 · 15 (11)

DOI: 10.1002/cam4.72463 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 05.11.2026. Verfasst von Yuxian Qian und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Researc…. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Primary‐tumor major pathological response (MPR) and postoperative nodal status are both used to assess response after neoadjuvant therapy for esophageal squamous cell carcinoma (ESCC), but discordant response after neoadjuvant chemoimmunotherapy is poorly characterized. We evaluated a combined primary tumor‐lymph node (PT‐LN) framework for risk stratification.

Methods

This retrospective single‐center cohort included patients treated with two cycles of paclitaxel, cisplatin, and camrelizumab followed by curative‐intent surgery between January 2019 and December 2024. Among 414 screened patients, 367 were included. MPR was defined as 10% or less residual viable tumor cells in the primary tumor. Patients were classified as PT‐MPR/ypN0, PT‐MPR/ypN+, PT‐non‐MPR/ypN0, or PT‐non‐MPR/ypN+. Disease‐free survival (DFS), overall survival (OS), first documented recurrence, and pathological model performance were evaluated.

Results

Sixty‐nine patients (18.8%) had PT‐MPR/ypN+ disease. DFS and OS differed across groups (both overall log‐rank p < 0.001). Compared with PT‐MPR/ypN0, PT‐MPR/ypN+ was associated with worse DFS (baseline‐adjusted hazard ratio [HR], 5.85; 95% confidence interval [CI], 2.82–12.14) and OS (HR, 18.06; 95% CI, 5.53–59.06; both p < 0.001), with similar conclusions after additional pathological adjustment. Regional lymph node recurrence occurred in 44.9% of PT‐MPR/ypN+ patients versus 3.6%, 6.7%, and 16.7% in the other groups (global p < 0.001). The combined PT‐LN framework had 3‐year DFS and OS AUCs of 0.798 and 0.818, with modest gains over LN‐only classification.

Conclusions

Residual nodal disease despite primary‐tumor MPR identifies an adverse phenotype with predominantly regional nodal recurrence. The combined framework is an interpretable stratification approach requiring external validation; surveillance and treatment implications remain hypothesis‐generating.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoadjuvant TherapyEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaAntineoplastic Combined Chemotherapy ProtocolsImmunotherapyHumansRetrospective StudiesFemaleMaleMiddle AgedAgedLymphatic MetastasisLymph NodesCisplatinPathologic Complete ResponsePaclitaxel

Stichwörter der Autor:innen

esophageal squamous cell carcinomamajor pathological responseneoadjuvant chemoimmunotherapypathological responsepostoperative risk stratificationresidual nodal disease

Substanzen

CisplatinPaclitaxel

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, P. R. China.
  • Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Cancer Institute of Jiangsu Province, Nanjing, P. R. China.
  • The Fourth Clinical College of Nanjing Medical University, Nanjing, P. R. China.
  • Department of Thoracic Surgery, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, P. R. China.
  • Department of Thoracic Surgery, The Fourth Affiliated Hospital of Soochow University, Soochow, P. R. China.

ORCID-Profile: Zhiyun Xu, Gaochao Dong, Feng Jiang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Qian, Y., Ren, Y., Xu, Z., Li, R., Feng, Y., Ding, H., Zhang, Y., Xia, W., Xu, L., Dong, G., & Jiang, F. (2026). Discordant Primary Tumor and Nodal Response After Neoadjuvant Chemoimmunotherapy Identifies an Adverse Postoperative Subgroup in Esophageal Squamous Cell Carcinoma. Cancer Medicine, 15(11). https://doi.org/10.1002/cam4.72463

Vancouver

Qian Y, Ren Y, Xu Z, Li R, Feng Y, Ding H, et al. Discordant Primary Tumor and Nodal Response After Neoadjuvant Chemoimmunotherapy Identifies an Adverse Postoperative Subgroup in Esophageal Squamous Cell Carcinoma. Cancer Medicine. 2026;15(11). doi:10.1002/cam4.72463

BibTeX
@article{Qian2026,
  author = {Qian, Yuxian and Ren, Yuting and Xu, Zhiyun and Li, Rutao and Feng, Yipeng and Ding, Hanlin and Zhang, Yijian and Xia, Wenjie and Xu, Lin and Dong, Gaochao and Jiang, Feng},
  title = {Discordant Primary Tumor and Nodal Response After Neoadjuvant Chemoimmunotherapy Identifies an Adverse Postoperative Subgroup in Esophageal Squamous Cell Carcinoma},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {11},
  doi = {10.1002/cam4.72463}
}
Kostenlos starten →